JP2023506834A5 - - Google Patents
Info
- Publication number
- JP2023506834A5 JP2023506834A5 JP2022536639A JP2022536639A JP2023506834A5 JP 2023506834 A5 JP2023506834 A5 JP 2023506834A5 JP 2022536639 A JP2022536639 A JP 2022536639A JP 2022536639 A JP2022536639 A JP 2022536639A JP 2023506834 A5 JP2023506834 A5 JP 2023506834A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding site
- seq
- amino acid
- multispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946932P | 2019-12-11 | 2019-12-11 | |
| US62/946,932 | 2019-12-11 | ||
| PCT/US2020/064672 WO2021119531A1 (en) | 2019-12-11 | 2020-12-11 | Anti-serum albumin antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506834A JP2023506834A (ja) | 2023-02-20 |
| JP2023506834A5 true JP2023506834A5 (cg-RX-API-DMAC7.html) | 2023-12-18 |
| JP7734132B2 JP7734132B2 (ja) | 2025-09-04 |
Family
ID=76329090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022536639A Active JP7734132B2 (ja) | 2019-12-11 | 2020-12-11 | 抗血清アルブミン抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230032087A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4073114A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7734132B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115916816B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020403153A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3161411A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293780A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119531A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115916818A (zh) | 2019-12-11 | 2023-04-04 | 库利南肿瘤股份有限公司 | 抗cd19抗体和多特异性结合蛋白 |
| JP2025526875A (ja) * | 2022-08-17 | 2025-08-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 改善された抗アルブミンナノボディおよびその使用 |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025201474A1 (zh) * | 2024-03-28 | 2025-10-02 | 诺纳生物(苏州)有限公司 | 血清白蛋白结合蛋白及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5185624B2 (ja) * | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体 |
| US8007796B2 (en) * | 2005-12-16 | 2011-08-30 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| CN101903403B (zh) * | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| MY167125A (en) * | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| EP3297672B1 (en) * | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3356405B1 (en) * | 2015-10-02 | 2026-07-08 | F. Hoffmann-La Roche AG | Anti-human cd19 antibodies with high affinity |
| ES3056995T3 (en) * | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| WO2019077062A1 (en) * | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | C-CELLS ACTIVATED BY BIT |
| CN113195544A (zh) * | 2018-06-07 | 2021-07-30 | 库利南肿瘤股份有限公司 | 多特异性结合蛋白及其使用方法 |
| CN119306844A (zh) * | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
-
2020
- 2020-12-11 US US17/785,011 patent/US20230032087A1/en not_active Abandoned
- 2020-12-11 JP JP2022536639A patent/JP7734132B2/ja active Active
- 2020-12-11 IL IL293780A patent/IL293780A/en unknown
- 2020-12-11 CN CN202080096427.XA patent/CN115916816B/zh active Active
- 2020-12-11 EP EP20899790.8A patent/EP4073114A4/en active Pending
- 2020-12-11 AU AU2020403153A patent/AU2020403153A1/en active Pending
- 2020-12-11 CA CA3161411A patent/CA3161411A1/en active Pending
- 2020-12-11 WO PCT/US2020/064672 patent/WO2021119531A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2025111463A5 (cg-RX-API-DMAC7.html) | ||
| JP2022177090A5 (cg-RX-API-DMAC7.html) | ||
| JP2021534762A5 (cg-RX-API-DMAC7.html) | ||
| JP2024522360A5 (cg-RX-API-DMAC7.html) | ||
| JP2021508469A5 (cg-RX-API-DMAC7.html) | ||
| JP2024510098A5 (cg-RX-API-DMAC7.html) | ||
| CN111417653A (zh) | Cd47抗原结合分子 | |
| JP2020525032A5 (cg-RX-API-DMAC7.html) | ||
| JP2022533538A5 (cg-RX-API-DMAC7.html) | ||
| JP2020515277A5 (cg-RX-API-DMAC7.html) | ||
| JP7836033B2 (ja) | Gprc5d抗体及びその応用 | |
| JP2023545183A5 (cg-RX-API-DMAC7.html) | ||
| JP2023506017A5 (cg-RX-API-DMAC7.html) | ||
| JP2025038088A5 (cg-RX-API-DMAC7.html) | ||
| JP2024540148A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516098A5 (cg-RX-API-DMAC7.html) | ||
| JP2021512652A5 (cg-RX-API-DMAC7.html) | ||
| JP2024546763A5 (cg-RX-API-DMAC7.html) | ||
| CN117586412A (zh) | 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法 | |
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2025511135A5 (cg-RX-API-DMAC7.html) | ||
| JP2025513714A5 (cg-RX-API-DMAC7.html) | ||
| IL277899B2 (en) | Methods and preparations for treating yellow fever |